![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Janssen Nabs Breakthrough Therapy Designation for Lung Cancer Treatment
Janssen Nabs Breakthrough Therapy Designation for Lung Cancer Treatment
The FDA granted breakthrough therapy designation to Janssen’s novel antibody JNJ-6372 for treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.
The agency granted the designation based on positive results from a phase 1 trial of JNJ-6372 as a monotherapy and in combination with lazertinib.
Janssen entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib.
Upcoming Events
-
21Oct